Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages 1350-1357

  Ris, M Douglas ^a   Walsh, Karin ^b   Wallace, Dana ^c   Armstrong, F Daniel ^d   Holmes, Emi ^e   Gajjar, Amar ^c   Packer, Roger J ^f  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f Center for Neuroscience and Behavioral Medicine   (United States)

Author keywords

Academic; Brain tumor; Cognitive; Intellectual; Medulloblastoma; Pediatric

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; LOMUSTINE; VINCRISTINE;

ACADEMIC ACHIEVEMENT; ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CRANIOSPINAL IRRADIATION; DEMOGRAPHY; DETERIORATION; FEMALE; HUMAN; INTELLECT; INTELLIGENCE QUOTIENT; INTELLIGENCE TEST; MALE; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; MUTISM; OUTCOME ASSESSMENT; PARENT; PRESCHOOL CHILD; PRIORITY JOURNAL; READING; SCHOOL CHILD;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIOSPINAL IRRADIATION; EDUCATIONAL STATUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTELLIGENCE; INTELLIGENCE TESTS; MALE; MEDULLOBLASTOMA;

EID: 84879245959     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24496     Document Type: Article

References (21)

1. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of cranial radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-4208.
2. Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 2001;19:3470-3476.
3. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 1998;16:1723-1728.
4. Mulhern RK, Palmer SL, Reddick WE, et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001;19:472-479.
5. Mabbott DJ, Noseworthy MD, Bouffet E, et al. Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: Correlation with IQ. Neuro Oncol 2006;8:244-252.
6. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: Implications for neuroprotection. Mol Interv 2004;4:273-284.
7. Monje ML, Vogel H, Masek M, et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007;62:515-520.
8. Spiegler BJ, Bouffet E, Greenburg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004;22:208-212.
9. Palmer SL, Gajjar A, Reddick WE, et al. Predicting intellectual outcome among children treated with 35-40Gy craniospinal irradiation for medulloblastoma. Neuropsychology 2003;17:548-555.
10. Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: A prospective study by the Children's Oncology Group. J Neurosurg 2006;104:444-451.
11. Grill J, Viguier D, Kieffer V, et al. Critical risk factors for intellectual impairment in children with posterior fossa tumors: The role of cerebellar damage. J Neurosurg Pediatr 2004;101:152-158.
12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
13. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005;23:5511-5519.
14. Wells EM, Khademian ZP, Walsh KS, et al. Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: Neuroradiologic features and origin. J Neurosurg Pediatr 2010;5:329-334.
15. Dennis M. Childhood medical disorders and cognitive impairment: Biological risk, time, development, and reserve. In: Yeates KO, Ris MD, Taylor HG, editors. Pediatric neuropsychology: Research, theory, and practice. New York: Guilford Press; 2000. 3 pp.
16. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-460.
17. Wechsler D. WISC-III manual. San Antonio, TX: The Psychological Corporation; 1991.
18. Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Onco 2009;11:201-210.
19. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005;23:7621-7631.
20. Grill CC, Figarella-Branger D, Bernier V, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: Long-term results of MSFOP 98. J Clin Oncol 2009;27:1879-1883.
21. Merchant TE, Hua CH, Shukla H, et al. Proton versus photon radiotherapy for common pediatric brain tumors: Comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008;51:110-117.